Indeed, in patients with metastatic melanoma, an anti-CTLA-4 treatment in combination with bevacizumab (an anti-VEGF monoclonal antibody) elicits humoral immunity to Gal-3 and Gal-1; those bi-therapy-treated metastatic patients have improved OS [117]. This evidence concerns the gene CTLA4 and metastatic melanoma.